JANX011
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune
Conditions
Autoimmune
Trial Timeline
Feb 1, 2026 → Dec 1, 2026
NCT ID
NCT07291323About JANX011
JANX011 is a phase 1 stage product being developed by Janux Therapeutics for Autoimmune. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07291323. Target conditions include Autoimmune.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07291323 | Phase 1 | Recruiting |
Competing Products
20 competing products in Autoimmune